Quick facts

Last updated: 1 June 2018

GSK House, UK

Quick facts

Download this information as a PDF

Pharmaceuticals

  • Our Pharmaceuticals business has a broad portfolio of innovative and established medicines.
  • We have been a leader in respiratory medicine for nearly 50 years and remain at the forefront of scientific research in this area, offering innovative medicines aimed at treating patients’ symptoms and reducing the risk of their disease worsening
  • We also have a long-standing commitment to HIV and are investigating new paradigms for treatment, prevention and cure
  • In 2017, we had two best-in-class medicines approved: Trelegy Ellipta, our once-daily triple therapy for chronic obstructive pulmonary disease (COPD) in a single inhaler; and Juluca, the first two-drug regimen, once-daily, single pill for HIV

Find out more about our Pharmaceuticals business

Vaccines

  • Our Vaccines portfolio is the largest in the industry, with vaccines for use at every stage of peoples' lives
  • A portfolio of more than 40 vaccines offer protection against 22 diseases and another 14 vaccines in our development pipeline
  • We distribute two million vaccines per day to people in over 160 countries
  • ~4 in 10 children globally receive at least one GSK vaccine
  • The Wavre site (Belgium) is the largest vaccines manufacturing site anywhere in the world

Find out more about our Vaccines business

Consumer Healthcare

  • Our Consumer Healthcare business is focused on five key areas: Pain Relief, Respiratory, Oral Health, Nutrition/ Gastro Intestinal and Skin Health
  • The seven power brands are Sensodyne (oral health), Polident/Poligrip/Corega (denture care), Parodontax/Corsodyl (gum health), Otrivin, Panadol, Voltaren and Theraflu
  • Our Consumer business is growing ahead of peers
    13% of Consumer Healthcare sales in 2017 were from product innovations launched over the past three years
    #1 in core OTC globally and in 36 markets
    #1 in specialist oral health globally and in 50 markets
    #1 in Specialist Oral Health and Pain Relief
    Sensodyne became the first £1bn consumer healthcare brand in 2016

Find out more about our Consumer Healthcare business

GSK in the UK

  • ~17,000 regular employees in the UK, ~3,000 contingent workers
    ~6,800 manufacturing employees
    ~4,100 R&D employees (across Rx and Cx)
    ~550 Pharma employees / ~80 Vaccines employees / ~700 Consumer Healthcare employees / ~150 ViiV Healthcare employees
  • Largest pharmaceutical company by value (and headquartered) in the UK
  • We are one of the largest private R&D investors in the UK, contributing around 26% of the UK pharmaceutical sector’s investment in UK R&D, and spend around a quarter of our global R&D budget here (>£1bn per year)
  • Global R&D hub at Stevenage
  • 8 manufacturing sites (Barnard Castle, Irvine, Maidenhead, Montrose, Slough, Ulverston, Ware and Worthing)
  • We have completed manufacturing investments of ~£1.3bn since 2012
  • We export ~80% of what we make in the UK

GSK in the US

  • ~15,000 employees
  • Network of scientists working in the US including a Global Pharma R&D hub in Upper Providence (Pennsylvania) and a Global Vaccines R&D Centre in Rockville (Maryland)
  • 9 manufacturing sites including:
    3 Pharma: Upper Merion (Pennsylvania), Rockville (Maryland) and Zebulon (North Carolina)
    4 Consumer: Oak Hill (New York), Memphis (Tennessee), St. Louis (Missouri) and Lincoln (Nebraska)
    2 Vaccines: Marietta (Pennsylvania), Hamilton (Montana)

Find out more about what we are doing across the US

R&D/Pipeline

  • As GSK and through our heritage companies, we have a 150-year legacy of applying science to discover and develop new medicines, vaccines and consumer healthcare products that help to transform lives
  • 2017 total R&D expenditure: £3.9bn
  • ~11,500 R&D employees globally

Trust/Corporate Responsibility and Global Public Health

  • GSK has topped the Access to Medicine Index since the biennial assessment began in 2008. In 2017, we also led the industry in the first ever Access to Vaccines Index, as well as the first Anti-Microbial Resistance Benchmark in early 2018
  • We were ranked no. 1 in the AllTrials Transparency Index, building on our long-standing commitment to transparency in clinical trials
  • We improved our ranking from third to second in our industry in the Dow Jones Sustainability World and Europe Indexes in 2017. This places us in the top 2% of our sector for economic, environmental and social performance
  • Our RTS,S vaccines is the only malaria vaccines that has received a positive scientific opinion from the European Medicines Agency (EMA) and a recommendation for pilot implementation by the WHO
  • We have reached 2.7 million children in 41 countries with life-saving interventions since the beginning of our five-year partnership with Save the Children
  • We have cut operational carbon emissions by 21% since 2010. Total value chain emissions have risen by 4% as we extend access to our medicines, and we are working to address this

Read more in our Responsible Business Supplement 2017